Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia
Phase of Trial: Phase I/II
Latest Information Update: 18 May 2018
At a glance
- Drugs RP L102 (Primary)
- Indications Fanconi's anaemia
- Focus Therapeutic Use
- 18 May 2018 According to a Rocket Pharmaceuticals media release, Julian Sevilla, M.D., Ph.D., of the hospital of Nino Jesus in Madrid, is the principal investigator of this trial. Five patients have been treated to date.
- 18 May 2018 According to a Rocket Pharmaceuticals media release, data from this trial was presented at the Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) annual meeting (2018).
- 18 May 2018 Results presented in the Rocket Pharmaceuticals media release.